| P/E (FY) | — | Sales (TTM) | $97.4M |
| Earnings (TTM) | -$172.4M | ROE | −14.00% |
| Net Margin | −73.20% | ROIC | −18.72% |
| Debt / Equity | 0.19 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | −8.62% |
Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibodies for cancer and autoimmune diseases. Its marketed products include Ultomiris for atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica, and Monjuvi for relapsed or refractory diffuse large B-cell lymphoma. Its pipeline includes bispecific antibodies such as XmAb819, XmAb541, XmAb808, XmAb942, plamotamab, and XmAb657 across oncology and inflammatory indications.
| Market Cap | $1.48B | Trading Days | 3179 |
| 52W High | 21.25 |
| 52W Low | 6.92 |
| % Off High | −6.02% |
| YTD | 30.44% | 1Y | 121.15% |
| 3Y | −16.76% | 5Y | −37.92% |
| 10Y | 7.60% | Since incept. (ann.) | 7.15% |
Reportable 100%
| Ann. Volatility (1Y) | 66.54% | Ann. Volatility (3Y) | 60.94% |
| Sharpe (1Y) | 1.53 | Sharpe (3Y) | 0.22 |
| Max Drawdown (1Y) | −42.61% | Max Drawdown (3Y) | −73.92% |
| Beta (3Y, vs SPY) | 1.05 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PAHC | PHIBRO ANIMAL HEALTH CORP | $1.48B | 30.6 |
| HROW | HARROW, INC. | $1.47B | — |
| CMPS | COMPASS Pathways plc | $1.46B | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.46B | — |
| ANAB | ANAPTYSBIO, INC | $1.52B | — |
| SEPN | Septerna, Inc. | $1.53B | — |
| PRGO | PERRIGO Co plc | $1.43B | — |
| XERS | Xeris Biopharma Holdings, Inc. | $1.42B | — |
| AVBP | ArriVent BioPharma, Inc. | $1.40B | — |
| MLTX | MoonLake Immunotherapeutics | $1.38B | — |
| INVA | Innoviva, Inc. | $1.61B | 6.6 |
| ABCL | AbCellera Biologics Inc. | $1.62B | — |